Search academic texts

Information × Registration Number 0219U000968, 0118U003727 , R & D reports Title Identify ways to reduce disability in patients with localized kidney cancer based on the development and optimization of innovative diagnostic methods, neoadjuvant targeted therapy and surgical treatment. popup.stage_title Head Stakhovskyy Eduard Oleksandrovich, Registration Date 21-03-2019 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The subject of the study - 118 patients with localized renal cell carcinoma. The purpose of the work is to improve the organ-saving tactics of treatment of localized kidney cancer by developing indications for non-adjuvant targeting therapy, assessing anatomic-morpho-functional changes and remote results of surgical treatment. Methods of research: clinical, laboratory, beam, statistical. It was found that the neoadjuvant regimen of targeted therapy in patients with localized NKR significantly (? 2 = 7.4; p <0.005) reduces the level of side effects from 63% to 38% compared with adjuvant, due to the greater number of functioning kidney parenchyma and higher levels of glomerular filtration (Mann-Whitney U test; p <0.005). It was established that the optimal term for neoadjuvant targeted therapy in patients with localized NKR is the use of 2 cycles. An increase in the number of cycles of therapy leads to an increase in the duration and cost of treatment, a slight increase in the number of side effects of TT by 17% in the absence of further regression of NSC, which does not affect the choice of type of surgical intervention, the level of intraoperative blood loss, duration of operation and hospitalization (p> 0.05 ) It was determined that conduction of neoadjuvant TT in patients with localized NK resulted in a significant tumor regression of 20.5 ± 14.3% on average, with a size of the primary tumor of 60.7 ± 19.8 mm, which ensured the possibility of organo-preserving surgical treatment in 91.4% of cases compared with 33.3% among patients without TT (x2 = 42.1; p <0.0001). A new system for predicting tumor regression level due to neoadjuvant targeting therapy is developed, which allows 95% confidence to determine the effectiveness of reducing its size and determine the feasibility of such treatment. It is shown that the low level of regression of NKR from 4th century. The histopathological gradation of nuclei in Furman (3.8 ± 2.9%) indicates a low efficiency of targeted therapy in the treatment of this category of patients (ANOVA:? 2 = 0.13; power = 0.72; p <0.05), and can be used as a predictive marker response. The research results were implemented at the National Cancer Institute, the Odessa Regional Clinical Oncology Center, and the Dnipro Municipal Clinical Hospital. Prognostic assumptions about the development of the object of the study are the reduction of the number of nephrectomies due to the reduction of tumor size under the influence of neoadjuvant targeted therapy in patients with localized renal cell carcinoma. Product Description popup.authors Вітрук Юрій Васильович Войленко Олег Анатолійович Вукалович Петро Семенович Гаврилюк Оксана Миколаївна Кононенко Олексій Анатолійович Пікуль Максим Валентинович Пілін Е. Семко С. Стаховський Едуард Олександрович Стаховський Олександр Едуардович popup.nrat_date 2020-04-02 Close